Literature DB >> 7881710

[Effects of nasal continuous positive airway pressure on lung function in patients with sleep obstructive apnea syndrome].

R Vázquez Oliva1, S Cano Gómez, F Capote Gil, M A Sánchez Armengol, C Carmona Bernal, J Castillo Gómez.   

Abstract

Sixty-one patients with obstructive sleep apnea syndrome (OSAS), 26 of whom also had chronic obstructive pulmonary disease (COPD), received treatment by nasal continuous positive airways pressure (nCPAP). To evaluate the effects of this device on daytime lung function, we analyzed pulmonary function tests before treatment with nCPAP and after a mean follow-up period of 12 months (range: 2-22 months). In patients with both OSAS and COPD, we observed a significant decrease in PaCO2 (p < 0.007), in airways resistance (p < 0.002) and in residual volume (p < 0.01); for these same patients we recorded increases in forced vital capacity (p < 0.04) and maximum inspiratory pressure (p < 0.02). We saw no change in lung function in patients with OSAS only. PaO2 increased after treatment in the 15 patients who were initially hypoxemic (p < 0.001). We conclude that after treatment with nCPAP, the greatest changes in respiratory function occur in patients with both OSAS and COPD, who also experience slight decrease in body weight. These changes may be explained by a decrease in auto-PEEP and weight loss.

Entities:  

Mesh:

Year:  1995        PMID: 7881710     DOI: 10.1016/s0300-2896(15)30982-0

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  2 in total

1.  Lack of benefit of continuous positive airway pressure on lung function in patients with overlap syndrome.

Authors:  Aidan O'Brien; Kristy Whitman
Journal:  Lung       Date:  2005 Nov-Dec       Impact factor: 2.584

2.  Long-term effects of treatment with nasal continuous positive airway pressure on lung function in patients with overlap syndrome.

Authors:  Javier de Miguel; Jorge Cabello; José M F Sánchez-Alarcos; Rudolfo Alvarez-Sala; Domingo Espinós; José L Alvarez-Sala
Journal:  Sleep Breath       Date:  2002-03       Impact factor: 2.816

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.